{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:55:29Z","timestamp":1769385329123,"version":"3.49.0"},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and stable CML on tyrosine kinase inhibitor therapy. She received once-weekly semaglutide (0.5\u20131.5\u2009mg) for 6 months, alongside insulin glargine and dapagliflozin\/metformin. Clinical, biochemical, and molecular parameters were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 months, her HbA1c declined from 10.7 to 5.5%, fasting plasma glucose from 16.2 to 5.3\u2009mmol\/L, and body weight decreased by 18\u2009kg. Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1). The patient experienced only mild, transient gastrointestinal side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this complex case, semaglutide proved safe and effective for achieving glycemic control and weight reduction without compromising CML stability. These findings suggest that GLP-1 receptor agonists may be a viable therapeutic option for patients with coexisting T2DM, severe obesity, and stable CML, warranting further investigation in broader populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2025-1184","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:20:42Z","timestamp":1745400042000},"source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature"],"prefix":"10.1515","volume":"20","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University , Chongqing 400010 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chongqing University Central Hospital, Chongqing Emergency Medical Centre , 1 Jiankang Road , Yuzhong District, Chongqing 400014 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025122201304616118_j_med-2025-1184_ref_001","doi-asserted-by":"crossref","unstructured":"Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;1:100004.","DOI":"10.1016\/j.obpill.2021.100004"},{"key":"2025122201304616118_j_med-2025-1184_ref_002","doi-asserted-by":"crossref","unstructured":"Kafyra M, Kalafati IP, Stefanou G, Kourlaba G, Moulos P, Varlamis I, et al. A dietary intervention in adults with overweight or obesity leads to weight loss irrespective of macronutrient composition. Nutrients. 2024;16(17):2842.","DOI":"10.3390\/nu16172842"},{"key":"2025122201304616118_j_med-2025-1184_ref_003","doi-asserted-by":"crossref","unstructured":"Cortes J, Silver RT, Kantarjian H. Chronic myeloid leukemia. Holland\u2010Frei Cancer Medicine. Hoboken, New Jersey: Wiley-Blackwell; 2022. p. 1\u201311.","DOI":"10.1002\/9781119000822.hfcm116.pub2"},{"key":"2025122201304616118_j_med-2025-1184_ref_004","doi-asserted-by":"crossref","unstructured":"Ganguly BB, Mandal S, Banerjee D, Kadam NN. Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in chronic myeloid leukemia. J Cancer Res Ther. 2022;18(3):760\u20134.","DOI":"10.4103\/jcrt.JCRT_1755_20"},{"key":"2025122201304616118_j_med-2025-1184_ref_005","doi-asserted-by":"crossref","unstructured":"Haddad F, Kantarjian HP. Navigating the management of chronic phase CML in the era of generic BCR: ABL1 tyrosine kinase inhibitors. J Natl Compr Canc Netw. 2024;22(1):e237116.","DOI":"10.6004\/jnccn.2023.7116"},{"key":"2025122201304616118_j_med-2025-1184_ref_006","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Breccia M, Jabbour E, Mauro MJ, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):90.","DOI":"10.1186\/s13045-022-01309-0"},{"key":"2025122201304616118_j_med-2025-1184_ref_007","doi-asserted-by":"crossref","unstructured":"Ciftciler R. The effect of obesity and body mass index on hematologic malignancies. Metab Syndr Relat Disord. 2023;21(7):353\u201361.","DOI":"10.1089\/met.2023.0048"},{"key":"2025122201304616118_j_med-2025-1184_ref_008","doi-asserted-by":"crossref","unstructured":"Kumar V, Stewart JH. Obesity, bone marrow adiposity, and leukemia: time to act. Obes Rev. 2023;25(3):e13674.","DOI":"10.1111\/obr.13674"},{"key":"2025122201304616118_j_med-2025-1184_ref_009","doi-asserted-by":"crossref","unstructured":"Zhang Y, Li Y, Xue C-D, Li S, Gao Z, Qin K. Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms. Front Endocrinol. 2024;15:1396022.","DOI":"10.3389\/fendo.2024.1396022"},{"key":"2025122201304616118_j_med-2025-1184_ref_010","doi-asserted-by":"crossref","unstructured":"Asiri A, Al Qarni A, Bakillah A. The interlinking metabolic association between type 2 diabetes mellitus and cancer: molecular mechanisms and therapeutic insights. Diagnostics. 2024;14(19):2132.","DOI":"10.3390\/diagnostics14192132"},{"key":"2025122201304616118_j_med-2025-1184_ref_011","doi-asserted-by":"crossref","unstructured":"Nayan SI, Rahman MH, Hasan MM, Raj SMRH, Almoyad MAA, Li\u00f2 P, et al. Network based approach to identify interactions between Type 2 diabetes and cancer comorbidities. Life Sci. 2023;335:122244.","DOI":"10.1016\/j.lfs.2023.122244"},{"key":"2025122201304616118_j_med-2025-1184_ref_012","doi-asserted-by":"crossref","unstructured":"Ahmed K, Kaddoura R, Yassin MA. A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia. Front Med. 2022;9:1025392.","DOI":"10.3389\/fmed.2022.1025392"},{"key":"2025122201304616118_j_med-2025-1184_ref_013","unstructured":"Chawla R, Jaggi S. Medical management of diabesity. J Assoc Phys India. 2019;67(12):52\u20136."},{"key":"2025122201304616118_j_med-2025-1184_ref_014","doi-asserted-by":"crossref","unstructured":"Galstyan GR, Shestakova EA, Sklyanik IA. O\u0436\u0438pe\u043d\u0438e \u0438 caxap\u043d\u044b\u0439 \u0434\u0438a\u0431e\u0442 2 \u0442\u0438\u043fa: \u043fo\u0438c\u043a \u043ao\u043c\u043fpo\u043c\u0438cc\u043do\u0433o \u0442epa\u043fe\u0432\u0442\u0438\u0447ec\u043ao\u0433o pe\u0448e\u043d\u0438\u044f. Diabetes Mellit. 2017;20(4):270\u20138.","DOI":"10.14341\/DM8726"},{"key":"2025122201304616118_j_med-2025-1184_ref_015","doi-asserted-by":"crossref","unstructured":"Janez A, Muzurovic E, Bogdanski P, Czupryniak L, Fabryova L, Fras Z, et al. Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe diabetes and obesity expert group. Diabetes Ther. 2024;15:1865\u201392.","DOI":"10.1007\/s13300-024-01615-5"},{"key":"2025122201304616118_j_med-2025-1184_ref_016","doi-asserted-by":"crossref","unstructured":"Tsilingiris D, Vallianou NG, Spyrou N, Kounatidis D, Christodoulatos GS, Karampela I, et al. Obesity and leukemia: biological mechanisms, perspectives, and challenges. Curr Obes Rep. 2024;13:1\u201334.","DOI":"10.1007\/s13679-023-00542-z"},{"key":"2025122201304616118_j_med-2025-1184_ref_017","doi-asserted-by":"crossref","unstructured":"Huang CE, Lee KD, Chang JJ, Tzeng HE, Huang SH, Yu LHL, et al. Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: a national population-based cohort study. Oncologist. 2024 Jan;29(1):e81\u20139.","DOI":"10.1093\/oncolo\/oyad225"},{"key":"2025122201304616118_j_med-2025-1184_ref_018","doi-asserted-by":"crossref","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351.","DOI":"10.1016\/j.molmet.2021.101351"},{"key":"2025122201304616118_j_med-2025-1184_ref_019","doi-asserted-by":"crossref","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390.","DOI":"10.2337\/dc22-1148"},{"key":"2025122201304616118_j_med-2025-1184_ref_020","doi-asserted-by":"crossref","unstructured":"Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10(1):117.","DOI":"10.3390\/cells10010117"},{"key":"2025122201304616118_j_med-2025-1184_ref_021","doi-asserted-by":"crossref","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326. 10.1016\/S0140-6736(21)01204-6.","DOI":"10.1016\/S0140-6736(21)01204-6"},{"key":"2025122201304616118_j_med-2025-1184_ref_022","doi-asserted-by":"crossref","unstructured":"Bartram CR, de Klein A, Hagemeijer A,  van Agthoven T, Geurts van Kessel A, Bootsma D, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277\u201380.","DOI":"10.1038\/306277a0"},{"key":"2025122201304616118_j_med-2025-1184_ref_023","doi-asserted-by":"crossref","unstructured":"Wang Y, Liang ZJ, Gale RP, Liao HZ, Ma J, Gong TJ, et al. Chronic myeloid leukaemia: biology and therapy. Blood Rev. 2024;65:101196.","DOI":"10.1016\/j.blre.2024.101196"},{"key":"2025122201304616118_j_med-2025-1184_ref_024","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845\u201350.","DOI":"10.1182\/blood-2011-06-362830"},{"key":"2025122201304616118_j_med-2025-1184_ref_025","doi-asserted-by":"crossref","unstructured":"Yan P, Wang Y, Fu T, Liu Y, Zhang ZJ. The association between type 1 and 2 diabetes mellitus and the risk of leukemia: a systematic review and meta-analysis of 18 cohort studies. Endocr J. 2021;68(3):281\u20139.","DOI":"10.1507\/endocrj.EJ20-0138"},{"key":"2025122201304616118_j_med-2025-1184_ref_026","doi-asserted-by":"crossref","unstructured":"MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst. 2005;97:1154\u20137.","DOI":"10.1093\/jnci\/dji209"},{"key":"2025122201304616118_j_med-2025-1184_ref_027","doi-asserted-by":"crossref","unstructured":"Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009;18:1501\u20136.","DOI":"10.1158\/1055-9965.EPI-09-0028"},{"key":"2025122201304616118_j_med-2025-1184_ref_028","doi-asserted-by":"crossref","unstructured":"Engeland A, Tretli S, Hansen S, Bj\u00f8rge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol. 2007;165:44\u201352.","DOI":"10.1093\/aje\/kwj353"},{"key":"2025122201304616118_j_med-2025-1184_ref_029","doi-asserted-by":"crossref","unstructured":"Abar L, Sobiecki JG, Cariolou M, Nanu N, Vieira AR, Stevens C, et al. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Ann Oncol. 2019;30:528\u201341.","DOI":"10.1093\/annonc\/mdz045"},{"key":"2025122201304616118_j_med-2025-1184_ref_030","doi-asserted-by":"crossref","unstructured":"Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB, Lenihan D. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. Clin Lymphoma Myeloma Leuk. 2017;17(10):676\u201383.","DOI":"10.1016\/j.clml.2017.06.011"},{"key":"2025122201304616118_j_med-2025-1184_ref_031","doi-asserted-by":"crossref","unstructured":"Tsilingiris D, Vallianou NG, Spyrou N, Kounatidis D, Christodoulatos GS, Karampela I, et al. Obesity and leukemia: biological mechanisms, perspectives, and challenges. Curr Obes Rep. 2024;13(1):1\u201334.","DOI":"10.1007\/s13679-023-00542-z"},{"key":"2025122201304616118_j_med-2025-1184_ref_032","doi-asserted-by":"crossref","unstructured":"Gao R, Man TS, Liang JH, Wang L, Zhu HY, Wu W, et al. Diabetes mellitus is associated with inferior prognosis in patients with chronic lymphocytic leukemia: a propensity score-matched analysis. Cancer Res Treat. 2020;52(1):189\u2013206.","DOI":"10.4143\/crt.2019.122"},{"key":"2025122201304616118_j_med-2025-1184_ref_033","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36(7):868\u201375.","DOI":"10.1016\/j.leukres.2011.12.020"},{"key":"2025122201304616118_j_med-2025-1184_ref_034","doi-asserted-by":"crossref","unstructured":"Dong Y, Cheng Y, Feng X, Yuan Z, Dong H, Zhang Y, et al. Association of obesity under different metabolic status with adverse outcomes in patients with chronic myeloid leukemia: a retrospective cohort study. J Diabetes. 2023;15(5):436\u201347.","DOI":"10.1111\/1753-0407.13383"},{"key":"2025122201304616118_j_med-2025-1184_ref_035","doi-asserted-by":"crossref","unstructured":"Le DH, Pham VH. HGPEC: a Cytoscape app for prediction of novel disease\u2010gene and disease\u2010disease associations and evidence collection based on a random walk on heterogeneous network. BMC Syst Biol. 2017;11(1):61.","DOI":"10.1186\/s12918-017-0437-x"},{"key":"2025122201304616118_j_med-2025-1184_ref_036","doi-asserted-by":"crossref","unstructured":"Ono K, Suzushima H, Watanabe Y, Kikukawa Y, Shimomura T, Furukawa N, et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern Med. 2012;51(19):2763\u20136.","DOI":"10.2169\/internalmedicine.51.8314"},{"key":"2025122201304616118_j_med-2025-1184_ref_037","doi-asserted-by":"crossref","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011 Sep;17(3):197\u2013202.","DOI":"10.1177\/1078155210378913"},{"key":"2025122201304616118_j_med-2025-1184_ref_038","doi-asserted-by":"crossref","unstructured":"Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95(8):3763\u20137.","DOI":"10.1210\/jc.2010-0086"},{"key":"2025122201304616118_j_med-2025-1184_ref_039","doi-asserted-by":"crossref","unstructured":"Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Investig. 2015;23(1):5\u201320.","DOI":"10.1515\/hmbci-2015-0016"},{"key":"2025122201304616118_j_med-2025-1184_ref_040","doi-asserted-by":"crossref","unstructured":"Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96(5):1723\u201332.","DOI":"10.1182\/blood.V96.5.1723.h8001723_1723_1732"},{"key":"2025122201304616118_j_med-2025-1184_ref_041","doi-asserted-by":"crossref","unstructured":"Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37(4):912\u201321.","DOI":"10.2337\/dc13-1518"},{"key":"2025122201304616118_j_med-2025-1184_ref_042","doi-asserted-by":"crossref","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399.","DOI":"10.1001\/jama.2015.9676"},{"key":"2025122201304616118_j_med-2025-1184_ref_043","doi-asserted-by":"crossref","unstructured":"Rajamand Ekberg N, Bodholdt U, Catarig AM, Catrina SB, Grau K, Holmberg CN, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark\/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15(5):871\u20138.","DOI":"10.1016\/j.pcd.2021.06.008"},{"key":"2025122201304616118_j_med-2025-1184_ref_044","doi-asserted-by":"crossref","unstructured":"Li P, Tang Z, Wang L, Feng B. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice. Mol Med Rep. 2017;16:3421\u20136.","DOI":"10.3892\/mmr.2017.6978"},{"key":"2025122201304616118_j_med-2025-1184_ref_045","doi-asserted-by":"crossref","unstructured":"Zhang L, Tian J, Diao S, Zhang G, Xiao M, Chang D. GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1beta-induced metabolic disturbance and mitochondrial dysfunction. Chem Biol Interact. 2020;332:109252.","DOI":"10.1016\/j.cbi.2020.109252"},{"key":"2025122201304616118_j_med-2025-1184_ref_046","doi-asserted-by":"crossref","unstructured":"Ismail AS, Yassin MA. Nilotinib-induced diabetes mellitus in a young female with chronic myeloid leukemia. Cureus. 2020;12(9):e10277.","DOI":"10.7759\/cureus.10277"},{"key":"2025122201304616118_j_med-2025-1184_ref_047","doi-asserted-by":"crossref","unstructured":"Iwamoto Y, Kimura T, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, et al. Nilotinib-induced diabetes in japanese patients with chronic myeloid leukemia. Intern Med. 2025;64(6):817\u201323. 10.2169\/internalmedicine.3740-24.","DOI":"10.2169\/internalmedicine.3740-24"},{"key":"2025122201304616118_j_med-2025-1184_ref_048","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","DOI":"10.1056\/NEJMoa022457"},{"key":"2025122201304616118_j_med-2025-1184_ref_049","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"2025122201304616118_j_med-2025-1184_ref_050","doi-asserted-by":"crossref","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 Mar;37(3):617\u201326.","DOI":"10.1038\/s41375-023-01829-9"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1184\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:33:22Z","timestamp":1766367202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1184\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,10,31]]}},"alternative-id":["10.1515\/med-2025-1184"],"URL":"https:\/\/doi.org\/10.1515\/med-2025-1184","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20251184"}}